Raymond James Financial
AKBA icon

Raymond James Financial’s Akebia Therapeutics AKBA Stock Holding History

Raymond James Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Sell
72,902
-7,675
-10% -$10.5K ﹤0.01% 5032
2025
Q4 		$130K Buy
80,577
+10,792
+15% +$22.6K ﹤0.01% 4879
2025
Q3 		$191K Buy
69,785
+10,283
+17% +$34.2K ﹤0.01% 4637
2025
Q2 		$217K Buy
59,502
+8,568
+17% +$23.5K ﹤0.01% 4479
2025
Q1 		$97.8K Buy
50,934
+6,186
+14% +$12.6K ﹤0.01% 4550
2024
Q4 		$85K Buy
+44,748
New +$77.7K ﹤0.01% 4548

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Raymond James Financial's AKBA Position: Q1 2026 in Review

Raymond James Financial reduced its Akebia Therapeutics (AKBA) stake by 9.5% in Q1 2026, selling an estimated $10.5K and leaving 72,902 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #5032.

Raymond James Financial first reported a position in AKBA in Q4 2024 and has held it in 6 quarters since. The position peaked at $217K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Raymond James Financial held 72,902 shares of Akebia Therapeutics worth $101K as of Q1 2026.
  • Raymond James Financial sold 7,675 Akebia Therapeutics shares in Q1 2026, an estimated $10.5K.
  • Akebia Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5032 holding.
  • Raymond James Financial first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Akebia Therapeutics position peaked at $217K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.